Novo Nordisk (NVO) Earnings Q2 2025
Share this content:
A box of ozempic and Vegavi made by Novo Nordisk at a pharmacy in London on March 8, 2024.
Holy Adams | Rooters
S Novo NordisIn the second quarter, Blockbuster Vegavi Weight Loss Drug has increased, the company said in its latest report that after cutting the entire year’s guidance and declared a new Chief Executive Officer.
Overall, the revenue has increased by continuous exchange rate every year to 76.86 billion Danish Chronar ($ 11.92 billion) in three months by the end of June.
The sale of his blockbuster Vegvi obesity drug increased by 67% during this period. Danish Croner Analyst estimated the $ 20 billion below 19.53 billion Danish Cronar.
The quarter net profit came to 26.5 billion Danish Cronar, which is expected of 26.6 billion Danish Croner analysts.
This is a developing story. Please check back for updates.
Post Comment